Pharmaceutical executive with more than two decades of strategic, cross-functional, and operational management roles in drug development, launch and life cycle management for global, regional and national markets, incl. Europe, Germany, USA. Strong record for being results-oriented as well as driving patient-focused innovation, with successful implementations in the areas of value demonstration & access, pricing & reimbursement, public affairs, and healthcare & payment policy, including rare diseases, orphan drugs and gene therapies.

Novartis Gene Therapies (formerly AveXis) is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, we are working to turn promising gene therapies into proven treatments, beginning with our transformative gene therapy for spinal muscular atrophy (SMA).